Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.
Benzinga ·